CA
NZ
UK
AU
IND
US
Private placements of this size are relatively uncommon for early clinical-stage biotech companies, and the involvement of Hansoh Pharma as a lead investor carries particular significance given that Hansoh is also the company that originally licensed AVR-001, Avere's lead drug candidate, to the business. …
Today's favorable reaction suggests that investors may have been more focused on the certainty and finalization of funding than on the incremental dilution associated with the raise. For small-cap biotech companies operating with limited cash runway, removing uncertainty about near-term financing availability can itself …
At the center of the deal is Utebzi, Spero's approved oral antibiotic currently partnered with GSK. Under the arrangement, Spero is trading away its rights to future milestone payments and net sales royalties tied to Utebzi in exchange for the $105 million in upfront …
At the center of the agreement is SP001, a Phase 2-ready anti-CD40L monoclonal antibody that Spero is in-licensing from Innovent. CD40L is a protein involved in immune cell signaling that plays a central role in numerous autoimmune and inflammatory conditions, and antibodies targeting this …
AVR-001's defining engineering feature is its approximately 100-hour half-life, which enables once-weekly oral administration. Achieving this kind of metabolic stability in a cyclic peptide is a notable technical accomplishment, as peptides have historically struggled to achieve the durability needed for infrequent oral dosing given …
The combined company will be guided by CEO Dr. Andrew Cheng and will prioritize AVR-001, a long-acting cyclic peptide IL-23 receptor antagonist licensed from Hansoh Pharma. Reverse mergers of this kind allow private companies like Avere to gain public market access by combining with …
Pluri Inc. (NASDAQ: PLUR) remains locked in negotiations with the European Investment Bank (EIB) over a €20 million loan repayment deadline, as the biotech firm seeks to avoid potential enforcement actions. The discussions, described as constructive, aim to resolve the loan’s terms before the …
Propanc Biopharma (NASDAQ: PPCB) confirmed a change to its board of directors. Long‑time director Annie Van Broekhoven stepped down, and the company named Carlo Campiciano as her successor.
West Pharmaceutical Services has formalized an updated collaboration with Daikyo Seiko, amending the cross‑license and distribution framework that originally began several years ago. The renewed agreements replace earlier versions and bring the partnership into the current reporting period.
Palvella Therapeutics (NASDAQ: PVLA) disclosed an investor presentation through a regulatory filing on July 14, 2026. The document, submitted to the U.S. Securities and Exchange Commission, serves as a corporate update for current and prospective shareholders. The filing aligns with disclosure requirements under the …
Please wait processing your request...